1. Home
  2. CRSP vs SAM Comparison

CRSP vs SAM Comparison

Compare CRSP & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • SAM
  • Stock Information
  • Founded
  • CRSP 2013
  • SAM 1984
  • Country
  • CRSP Switzerland
  • SAM United States
  • Employees
  • CRSP N/A
  • SAM N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • SAM Beverages (Production/Distribution)
  • Sector
  • CRSP Health Care
  • SAM Consumer Staples
  • Exchange
  • CRSP Nasdaq
  • SAM Nasdaq
  • Market Cap
  • CRSP 3.4B
  • SAM 3.5B
  • IPO Year
  • CRSP 2016
  • SAM 1995
  • Fundamental
  • Price
  • CRSP $40.53
  • SAM $251.86
  • Analyst Decision
  • CRSP Buy
  • SAM Hold
  • Analyst Count
  • CRSP 19
  • SAM 10
  • Target Price
  • CRSP $77.13
  • SAM $307.22
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • SAM 158.0K
  • Earning Date
  • CRSP 02-19-2025
  • SAM 02-25-2025
  • Dividend Yield
  • CRSP N/A
  • SAM N/A
  • EPS Growth
  • CRSP N/A
  • SAM N/A
  • EPS
  • CRSP N/A
  • SAM 6.70
  • Revenue
  • CRSP $202,829,000.00
  • SAM $2,004,349,000.00
  • Revenue This Year
  • CRSP N/A
  • SAM $0.72
  • Revenue Next Year
  • CRSP $724.16
  • SAM $2.42
  • P/E Ratio
  • CRSP N/A
  • SAM $37.65
  • Revenue Growth
  • CRSP 19.31
  • SAM N/A
  • 52 Week Low
  • CRSP $36.52
  • SAM $249.21
  • 52 Week High
  • CRSP $91.10
  • SAM $371.65
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.09
  • SAM 22.78
  • Support Level
  • CRSP $36.52
  • SAM $253.13
  • Resistance Level
  • CRSP $40.99
  • SAM $265.28
  • Average True Range (ATR)
  • CRSP 1.78
  • SAM 8.16
  • MACD
  • CRSP 0.23
  • SAM -3.98
  • Stochastic Oscillator
  • CRSP 51.68
  • SAM 4.73

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the us, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates over 95% of sales in the us.

Share on Social Networks: